GHP July 2016

ghp July 2016 | 59 Research & Development Patent JP 5934645 covers PQ912 and surrounding chemical space; this patent has been granted already in the USA, the EU as well as in other important markets. With a patent life expiring in 2030, plus the usual extension for pharmaceuticals, the patent provides a solid protection for PQ912 in Japan and other key markets. The claims of patent JP 5930573 cover the general use of QC inhibitors for the treatment of Mild Cognitive Impairment (MCI), granted previously for the treatment of AD and British / Danish dementia in the USA, EU and Japan, thereby broadly protecting the general use of QC inhibition. Importantly, the granted claims of JP 5930573, already issued in the US, complement and extend the use of QC inhibitors for MCI. Hans-Ulrich Demuth, co-founder, former CSO of Probiodrug and key inventor, commented: “These patents significantly strengthen Probiodrug’s position in Japan as Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announced that the Japanese Patent Office has granted the company two important patents. Patents nos. 5934645 (Heterocyclic derivatives as inhibitors of glutaminyl cyclase) and 5930573 (New use of glutaminyl cyclase inhibitors) were granted in Japan in May 2016. a key territory for developing and commercialising drugs for the treatment of Alzheimer’s disease. Together with the previously granted and issued patents in USA, Japan and other major markets, they enable Probiodrug to have a dominant patent position in the field of QC inhibition for the treatment of this devastating disease.” About Alzheimer’s disease Alzheimer’s disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer’s disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. Today, over 46 million people worldwide currently live with the condition and this number is expected to increase to 132 million by 2050. Alzheimer’s also has an estimated, global societal cost of US$ 818 billion (World Alzheimer Report 2015). For further information, please visit: